Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.37 |
| ▸ | CASP1 | P29466 | 2/20 | 0.34 |
| ▸ | BAZ2B | Q9UIF8 | 2/20 | 0.33 |
| ▸ | BAZ2A | Q9UIF9 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 2/20 | 0.32 |
| ▸ | MMP2 | P08253 | 2/20 | 0.32 |
| ▸ | MMP9 | P14780 | 2/20 | 0.32 |
| ▸ | MMP8 | P22894 | 2/20 | 0.32 |
| ▸ | MMP13 | P45452 | 2/20 | 0.32 |
| ▸ | MMP12 | P39900 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1966470 | 0.80 | SMN1; SMN2 (0.46) | CES1SMN1; SMN2GAANOX1MAPT | |
| Ethylene SCHEMBL28323501 | 0.75 | CASP1 (0.45) | MYCCASP1PTGS2SMN1; SMN2TSHR | |
| SCHEMBL232659 | 0.74 | CASP1 (0.47) | MYCCASP1PTGS2SMN1; SMN2TSHR | |
| SCHEMBL29743050 | 0.74 | CASP1 (0.47) | MYCCASP1PTGS2SMN1; SMN2TSHR | |
| Hydrochloric Acid SCHEMBL11757790 | 0.73 | CASP1 (0.46) | MYCCASP1PTGS2SMN1; SMN2TSHR | |
| SCHEMBL28934633 | 0.73 | CASP1 (0.46) | MYCCASP1PTGS2SMN1; SMN2TSHR | |
| Water SCHEMBL27371066 | 0.73 | CASP1 (0.46) | MYCCASP1PTGS2SMN1; SMN2TSHR | |
| Lithium SCHEMBL3173875 | 0.73 | CASP1 (0.46) | MYCCASP1PTGS2SMN1; SMN2TSHR | |
| SCHEMBL29194067 | 0.73 | CASP1 (0.46) | MYCCASP1PTGS2SMN1; SMN2TSHR | |
| SCHEMBL1870052 | 0.73 | CASP1 (0.46) | MYCCASP1PTGS2SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255091-A1 | COMPOUNDS TO TREAT AMYLOIDOSIS AND PREVENT DEATH OF BETA-CELLS IN TYPE 2 DIABETES MELLITUS | ASTRUM THERAPEUTICS PTY LTD. (AU) | 2008-10-16 | — | — | US | disclosed |
| EP-1879564-A2 | COMPOUNDS TO TREAT AMYLOIDOSIS AND PREVENT DEATH OF BETA-CELLS IN TYPE 2 DIABETES MELLITUS | Astrum Therapeutics Pty, Ltd. (AU) | 2008-01-23 | — | — | EP | disclosed |
| US-20060252819-A1 | Compounds to treat amyloidosis and prevent death of beta-cells in type 2 diabetes mellitus | ASTRUM THERAPEUTICS PTY LTD (AU) | 2006-11-09 | — | — | US | disclosed |
| WO-2006110477-A2 | COMPOUNDS TO TREAT AMYLOIDOSIS AND PREVENT DEATH OF BETA-CELLS IN TYPE 2 DIABETES MELLITUS | ASTRUM THERAPEUTICS PTY. LTD. (AU) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255091-A1 | COMPOUNDS TO TREAT AMYLOIDOSIS AND PREVENT DEATH OF BETA-CELLS IN TYPE 2 DIABETES MELLITUS | IAPP, BCL2, AMY2A | CES1 430/4885MYC 831/4885HSP90AA1 710/4885 |
| US-20060252819-A1 | Compounds to treat amyloidosis and prevent death of beta-cells in type 2 diabetes mellitus | IAPP, BCL2, AMY2A | CES1 430/4885MYC 831/4885HSP90AA1 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.